Essential thrombocytosis overview

	Essential thrombocytosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Epidemiology and Demographics
Risk Factors
Screening
Causes
Differentiating Essential thrombocytosis from other Diseases
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Essential thrombocytosis overview On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Essential thrombocytosis overview All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Essential thrombocytosis overview
CDC on Essential thrombocytosis overview
Essential thrombocytosis overview in the news
Blogs on Essential thrombocytosis overview
Directions to Hospitals Treating Essential thrombocytosis
Risk calculators and risk factors for Essential thrombocytosis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Essential thrombocytosis (ET, also known as essential thrombocythemia) is a rare chronic blood disorder characterized by the overproduction of platelets by megakaryocytes in the bone marrow in the absence of an alternative cause. In some cases this disorder may be progressive, and rarely may evolve into acute myeloid leukemia or myelofibrosis. It is one of four myeloproliferative disorders.